ASH 2018 Guidelines for Management of VTE:
Prophylaxis for Hospitalized and Non-Hospitalized Medical Patients

Supplement 2: Disclosure of Interest Forms of the Guideline Panel

Kenneth Bauer
Jan Beyer-Westendorf
Allison Burnett
Mary Cushman (chair)
Francesco Dentali
Susan Kahn
Jill Lansing
Suely Rezende
Holger J. Schünemann (vice-chair)
Frederick Spencer
Neil Zakai
ASH Guideline Panel
Declarations of Interest Form

Part A. Material Interests in Companies

**Equity**
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.
   - ☒ No
   - ☐ Yes, as described below:

   Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patents and Royalties**
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?
   - ☒ No
   - ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen Pharmaceutical</td>
<td>Consulting, DSMB Member</td>
<td>Ongoing</td>
<td>COI: Janssen markets rivaroxaban.</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Advisory Board</td>
<td>Ongoing</td>
<td>COI: BI markets dabigatran.</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>Advisory Board</td>
<td>3/2015</td>
<td>Ended before appointment.</td>
</tr>
<tr>
<td>Portola Pharmaceutical</td>
<td>Advisory Board</td>
<td>Ongoing</td>
<td>Possible COI: Portola is developing an anticoagulant reversal agent.</td>
</tr>
<tr>
<td>Instrumentation Lab</td>
<td>Advisory Committee</td>
<td>Ongoing</td>
<td>Instrumentation Laboratory markets laboratory and point-of-care instruments, assays, and reagents for whole blood and hemostasis testing. These products are not expected to be affected by guidelines on VTE prophylaxis.</td>
</tr>
</tbody>
</table>
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

| Column 1 | Name the company funding or supporting the research. |
| Column 2 | Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution. |
| Column 3 | Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
| Column 4 | Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No
☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention of VTE in Medical Hospitalized Patients

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs
1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes

   If yes, please explain:

Previously Published Opinions
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☒ No
   - ☐ Yes

   If yes, what were those views and where were they made?

Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
☒ No

☐ Yes, as described below:

**Column 1** Name the entity funding the research.

**Column 2** Describe the research project.

**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know

☒ No

☐ Yes
Kenneth Bauer, MD (Beth Israel Deaconess Medical Center)

If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Would be supported by my institution

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☒ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☒ No
☐ Yes

If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?

Hematology-Oncology
9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☒ No
☐ Yes

If yes, please explain:

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No
☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Prevention of VTE in Medical Hospitalized Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved to participate?</td>
<td>Status</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
</tbody>
</table>
If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen Pharmaceuticals</td>
<td>Personal income from consulting and from serving on a data safety monitoring board</td>
<td>4/29/2015</td>
<td>Janssen markets rivaroxaban.</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Personal income from serving on an advisory board</td>
<td>4/29/2015</td>
<td>Boehringer Ingelheim markets dabigatran.</td>
</tr>
<tr>
<td>Portola</td>
<td>Personal income from serving on an advisory board</td>
<td>4/29/2015</td>
<td>Potential COI: Portola is developing anticoagulant reversal agents.</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Personal income from serving on an advisory board</td>
<td>09/20/16</td>
<td>BMS markets apixaban and warfarin.</td>
</tr>
</tbody>
</table>

Notes:
## Part D. New Declarations

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portola</td>
<td>Personal income for an Advisory Board. This previously reported activity ended in December 2014.</td>
<td>09/20/16</td>
<td>Potential COI. Under ASH policy, past financial relationships are not generally considered a COI. However, before appointment to the guideline panel, Dr. Bauer described this activity as “ongoing” (see p. 2), suggesting that he expected possible continued payments for participating in the advisory board during the guideline development process. It therefore seems reasonable and conservative to continue to judge this ended activity as a potential COI. This judgment will have no impact on Dr. Bauer’s status or required recusal from recommendations if this product does not come to market during the guideline development process.</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Personal income from serving on an advisory board related to apixaban in December 2015</td>
<td>09/20/16</td>
<td>COI. BMS markets apixaban and warfarin.</td>
</tr>
<tr>
<td>Company</td>
<td>Description</td>
<td>Disclosure Date</td>
<td>ASH Internal Notes</td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td>Portola</td>
<td>Personal income from serving on an advisory board. This paid activity is has ended.</td>
<td>05/03/2018</td>
<td>This is an update to Part A, Question 3.</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Personal income from serving on an advisory board. This paid activity is has ended.</td>
<td>05/03/2018</td>
<td>This is an update to Part A, Question 3.</td>
</tr>
<tr>
<td>Instrumentation Lab</td>
<td>Personal income from serving on an advisory board. This paid activity is has ended.</td>
<td>05/03/2018</td>
<td>This is an update to Part A, Question 3.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☐ No
☒ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Stock (app. 2800 €</td>
<td>April 9 2015</td>
<td>Divested before appointment</td>
</tr>
<tr>
<td></td>
<td>worth)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.
### Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bayer</strong></td>
<td>Honoraria for lectures and advisory boards</td>
<td>ongoing</td>
<td>COI. Bayer markets rivaroxaban.</td>
</tr>
<tr>
<td><strong>Boehringer</strong></td>
<td>Honoraria for lectures and advisory boards</td>
<td>ongoing</td>
<td>COI. Boehringer-Ingelheim markets dabigatran.</td>
</tr>
<tr>
<td><strong>Pfizer</strong></td>
<td>Honoraria for lectures and advisory boards</td>
<td>ongoing</td>
<td>COI. Pfizer markets dalteparin and apixaban.</td>
</tr>
</tbody>
</table>

To report activities that generate revenues for your institution, see Part B, Question 4.
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>EINSTEIN CHOICE (trial on extended VTE</td>
<td>Member of SC, direct</td>
<td>ongoing</td>
<td>COI: affected</td>
</tr>
<tr>
<td></td>
<td>treatment)</td>
<td>payment</td>
<td></td>
<td>company (Bayer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>markets rivaroxaban)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>+ direct payment</td>
</tr>
<tr>
<td>Portola</td>
<td>APEX (VTE prevention trial)</td>
<td>Investigator (payment</td>
<td>ongoing</td>
<td>Not a COI: Payment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>to institution)</td>
<td></td>
<td>to institution + Dr.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Beyer is not the lead</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>investigator.</td>
</tr>
<tr>
<td>Portola</td>
<td>ADEXANET ALPHA (study on factor Xa</td>
<td>National lead investigator</td>
<td>ongoing</td>
<td>Possible COI: Portola</td>
</tr>
<tr>
<td></td>
<td>antidote)</td>
<td>Germany (payment to</td>
<td></td>
<td>is developing a new</td>
</tr>
<tr>
<td></td>
<td></td>
<td>institution)</td>
<td></td>
<td>AC reversal agent +</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>leadership role</td>
</tr>
<tr>
<td>Boehringer</td>
<td>REVERSE (study on dabigatran antidote)</td>
<td>Investigator (payment</td>
<td>ongoing</td>
<td>Not a COI: Payment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>to institution)</td>
<td></td>
<td>to institution + Dr.</td>
</tr>
</tbody>
</table>
My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☐ No

☐ Yes, as described below:

Add rows as needed for each interest.
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in Medical Hospitalized Patients

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

☐ No
☒ Yes

If yes, please explain:

As can be expected, I strongly believe that effective and safe VTE prevention is crucial also in medically ill patients. Several epidemiologic studies in the past 10 years clearly demonstrated the high risk for (potentially fatal) VTE in this cohort and clinical trials indicated that anticoagulants in general may effectively reduce this risk. Consequently, current guidelines such as ACCP recommend the use of medical thromboprophylaxis, to which I fully agree.

In the past 15 years I have been involved (both as investigator or as part of event adjudication committees) in several studies evaluating various anticoagulants in this indication (including fondaparinux, several low-molecular weight heparins, several non-VKA oral anticoagulants) and, based on these experiences, I feel unbiased regarding specific drugs but firmly believe in the necessity to provide effective and safe VTE prevention.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

☒ No
☐ Yes
If yes, what were those views and where were they made?

Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No
☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Name the entity funding the research.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column 2</td>
<td>Describe the research project.</td>
</tr>
<tr>
<td>Column 3</td>
<td>Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.</td>
</tr>
<tr>
<td>Column 4</td>
<td>Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Institutional Relationships
4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

This certainly is a difficult question. I would expect that invitation to a guideline panel is generally seen as a recognition of expertise. Since I am responsible for developing our institutional SOP’s on anticoagulation (both in prevention and treatment indications) I would expect that participation in the guideline panel would both help to better refine our SOP’s and to improve implementation. Apart from this benefit (on patient care) I cannot see any other relevant impact on my personal or professional life.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes

If yes, please explain:
Professional Specialty

8. What is your primary clinical specialty or subspecialty?

I hold specializations in
- Internal Medicine (since 2005)
- Intensive Care Medicine (since 2006)
- Vascular Medicine (since 2007) and
- Haemostaseology (since 2009).

I work as a consultant for Vascular Medicine and for Haemostasis at the University Hospital Dresden, Germany.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No
☒ Yes

If yes, please explain:

As stated above, I work as a consultant for Vascular Medicine and for Haemostasis in my hospital and, in this position, I am responsible for developing our institutional SOP’s on anticoagulation (both in prevention and treatment indications). These SOP’s partly relate also to VTE prevention in medically ill patients.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☐ No
☒ Yes

If yes, please describe:

Johnson & Johnson is conducting a trial (MARINER) in the field of extended VTE prevention in medically ill patients after discharge from hospital. This trial is currently not recruiting patients in Germany but the company has contacted me to assess feasibility of such a trial in Germany. The company has indicated that, if they will indeed extend the trial to Germany, they may consider me for the position of a National Coordinator. So far, no decision has been made and no contracts have been negotiated or signed.
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on VTE in Medical Hospitalized Patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer name and date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>4/15/15; 4/26/15</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>10/13/16 Alexander; 10/17/16 Kunkle; 10/21/16 Rajasekhar</td>
<td>New financial disclosures. See Part D.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>5/9/18 Alexander, Kunkle</td>
<td>On 5/4/2018, Dr. Beyer-Westendorf confirmed all information on this form is correct. Note: On 6/23/2017, FDA approved Portola’s betrixaban, and on 5/3/2018 FDA approved Portola’s andexanet alfa. These approvals occurred after the panel’s meeting on 11/17-18/2016, when all recommendations were finalized.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:
<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Honoraria for lectures and advisory boards</td>
<td>04/09/15</td>
<td>Bayer markets rivaroxaban.</td>
</tr>
<tr>
<td>Boehringer-Ingelheim</td>
<td>Honoraria for lectures and advisory boards</td>
<td>04/09/15</td>
<td>Boehringer-Ingelheim markets dabigatran.</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Honoraria for lectures and advisory boards</td>
<td>04/09/2015</td>
<td>Pfizer markets dalteparin and apixaban.</td>
</tr>
<tr>
<td>Bayer</td>
<td>Direct payment for membership on the steering committee for EINSTEIN CHOICE, a trial on extended VTE treatment</td>
<td>04/09/2015</td>
<td>Bayer markets rivaroxaban.</td>
</tr>
<tr>
<td>Portola</td>
<td>National lead investigator in Germany for ADEXANET ALPHA, a study on factor Xa antidote funded by Portola</td>
<td>04/09/2015</td>
<td>Possible COI: Portola is developing new anticoagulant drugs + Dr. Beyer has a leadership role. (Disclosure updated by Dr. Beyer-Westendorf on 9/21/16.)</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>Leadership role and direct payment received for coordinating research on VTE prevention in medically ill patients after discharge from the hospital</td>
<td>9/21/16</td>
<td>COI. Johnson &amp; Johnson owns Janssen, which markets rivaroxaban.</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>Direct payment for speaking and participation on advisory boards</td>
<td>9/21/16</td>
<td>COI. Daiichi Sankyo markets edoxaban.</td>
</tr>
</tbody>
</table>

Notes:

Some “possible” or “potential” COIs may or may not trigger recusal. Will need to evaluate at time of voting on recommendations.
Part D. New Declarations
The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daiichi Sankyo</td>
<td>Direct payments for speaking and participating on advisory boards</td>
<td>9/21/16</td>
<td>COI. Daiichi Sankyo markets edoxaban.</td>
</tr>
<tr>
<td>Portola</td>
<td>National lead investigator for Germany ADEXANET ALPHA study on factor Xa antidote. This is an update to a previously disclosed interest.</td>
<td>9/21/16</td>
<td>Possible COI: Portola is development new anticoagulant reversal agents, the subject of the research is related to VTE, and Dr. Beyer-Westendorf has a leadership role. By email, Dr. Beyer-Westendorf confirmed that she received direct payment for this project.</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>National Coordinator for trial on VTE prevention in medically ill patients after discharge from the hospital. Payment to institution in addition to direct payments to Dr. Beyer-Westendorf.</td>
<td>9/21/16</td>
<td>COI. Johnson &amp; Johnson owns Janssen, which markets rivaroxaban. Dr. Beyer-Westendorf has a leadership role in this research.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

| Column 1 Name the company funding or supporting the research. |
| Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution. |
| Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
| Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each research project.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:
Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in Medical Hospitalized Patients

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs
1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☐ No
   - ☒ Yes
   If yes, please explain:

   As a clinician, I believe we have a responsibility to identify hospitalized patients at risk for VTE and to employ evidence-based modalities in a timely manner and for appropriate durations to minimize thromboembolic events. The approach to VTE prophylaxis needs to be somewhat standardized, but the individual regimens need to be customized to each patient’s needs and characteristics, such as weight, renal function and preferences. I also believe that we need to be acutely aware of patients who are not at sufficient risk to ensure lack of exposure to potential risks, such as bleeding, posed by pharmacologic prophylaxis.

Previously Published Opinions
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☒ No
   - ☐ Yes
   If yes, what were those views and where were they made?
Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Name the entity funding the research.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column 2</td>
<td>Describe the research project.</td>
</tr>
<tr>
<td>Column 3</td>
<td>Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.</td>
</tr>
<tr>
<td>Column 4</td>
<td>Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
Yes

If yes, please explain:

I believe our institution would benefit in a clinical, non-financial manner. While we currently perform well in VTE prophylaxis measures, I feel that the bar is set fairly low in regards to core measures and meaningful use. Also, I believe that many institutions, including our own, fail to drill down as much as needed within the medicine patient population as to appropriateness (including dose, type and duration) of prophylaxis. This may serve as an opportunity to provide clear, concise recommendations or guidance to hospitalists or other clinicians in our institution, as well as others, as to best practices among medicine patients.

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I believe that my mentors, my institution and other entities that I am involved with in the field of anticoagulation would be supportive of my efforts and involvement. I strive to maintain objectivity and practice based on evidence. When asked to formulate recommendations in areas lacking solid evidence, I feel I have both real life, bedside experience, and a healthy network of expert resources, such as mentors, to reach out to for guidance. I will rely on each of these throughout the project, and as such, anticipate that my efforts will be supported even in the event of a strong reaction.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

Yes

If yes, are you involved in formulating or voting for positions?

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don’t know or not applicable

No
☐ Yes
If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?
   Anticoagulation

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
   ☒ Yes
   ☐ No

If yes, please explain:

My service (pharmacy-driven inpatient anticoagulation service) may recommend diagnostic tests to confirm or refute thrombotic events if they have not already been performed by the time we are consulted. More commonly, our service recommends against diagnostic testing (e.g. surveillance Doppler for DVT in asymptomatic trauma patients). We may recommend more definitive tests, such as CT angio rather than VQ scan, to optimize diagnosis.

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

   ☒ No
   ☐ Yes

If yes, please describe:
# Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Prevention of VTE in Medical Hospitalized Patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>04/15/2015; 04/25/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>4/25/2018 Alexander</td>
<td>On 4/21/2018, Dr. Burnett confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
</table>

Notes:
# ASH Guideline Panel

## Declarations of Interest Form

### Part A. Material Interests in Companies

**Equity**

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   *Add rows as needed for each equity interest.*

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patents and Royalties**

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   *Add rows as needed for each patent or royalty interest.*

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>diaDexus</td>
<td>Travel reimbursement to present research results of project funded by company (see grant below for detail – travel occurred after funding period)</td>
<td>March 2015</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>Merck</td>
<td>Single advisory board and brief consulting.</td>
<td>June 2014</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>Single advisory board</td>
<td>March 2014</td>
<td>Ended before appointment</td>
</tr>
</tbody>
</table>

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>diaDexus</td>
<td>LpPLA2 activity and risk of coronary heart disease, stroke and cognitive impairment - I expect a new grant soon from this company to continue this work. It is totally unrelated to topic of the guideline</td>
<td>PI</td>
<td>12/2014.</td>
<td>Ended before appointment</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.
My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention of VTE in Medical Hospitalized Patients

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes
   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☐ No
   - ☒ Yes
   If yes, what were those views and where were they made?
   I was an author on the last ACCP guideline chapter on this topic. This did not involve me stating a personal opinion.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
☒ Yes, as described below:

**Column 1** Name the entity funding the research.

**Column 2** Describe the research project.

**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemophilia and Thrombosis Research Society</td>
<td>Risk factors for venous thrombosis in hospitalized medical patients</td>
<td>I was the mentor of this mentored research award. Funding ended &gt;3 years ago but the work is ongoing. It involved identification of risk factors.</td>
<td>Ongoing project without funding</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would think this would be considered a favorable thing.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☒ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☒ No
☐ Yes

If yes, please explain:
Professional Specialty
8. What is your primary clinical specialty or subspecialty?
   Hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
   ☒ Yes
   If yes, please explain:
   My practice is devoted to caring for patients with thrombosis related disorders, including venous thrombosis. I direct a clinical and research group that is interested in prevention of thrombosis.

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
    ☒ No
    ☐ Yes
    If yes, please describe:
### Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Prevention of VTE in Medical Hospitalized Patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Date reviewed by ASH staff</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/1/2015; 5/3/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/10/2018 Alexander</td>
<td>On 4/30/2018, Dr. Cushman confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
</table>

Notes:
ASH Guideline Panel
Declarations of Interest Form

Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that
develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose,
treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and
other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from
any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health
conditions?

☒ No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

Column 1  Name the company.

Column 2  Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3  Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAYER</td>
<td>LECTURE</td>
<td>May 2015</td>
<td>COI: Bayer markets rivaroxaban.</td>
</tr>
<tr>
<td>BOEHRINGER</td>
<td>LECTURE</td>
<td>May 2015</td>
<td>COI: Boehringer Ingelheim markets dabigatran.</td>
</tr>
<tr>
<td>BOHERINGER</td>
<td>CONSULTANCY</td>
<td>2015 (ongoing)</td>
<td>COI: Boehringer Ingelheim markets dabigatran.</td>
</tr>
<tr>
<td>BAYER</td>
<td>CONSULTANCY</td>
<td>2014</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>BMS/PFIZER</td>
<td>ADVISORY BOARD</td>
<td>March 2015</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>BOHERINGER</td>
<td>ADVISORY BOARD</td>
<td>March 2015</td>
<td>Ended before appointment</td>
</tr>
</tbody>
</table>
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

Column 1  Name the company funding or supporting the research.

Column 2  Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Observational study on the prevalence and risk factors for concomitant deep vein thrombosis in patients with objectively diagnosed superficial vein thrombosis. I would underline that this is not a pharmacological study</td>
<td>PI</td>
<td>Ongoing</td>
<td>COI: Bayer markets rivaroxaban + leadership role + subject of research is relevant to guideline topics</td>
</tr>
</tbody>
</table>

AS狮 Guideline Panel Declarations of Interests Form | Page 3
My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No
☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in Surgical Hospitalized Patients, Prevention of VTE in Medical Patients, and Optimal Management of Anticoagulation Therapy

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs
1. Do you have strongly held beliefs related to the topic of these guidelines?
   ☒ No
   ☐ Yes
   If yes, please explain:

Previously Published Opinions
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   ☒ No
   ☐ Yes
   If yes, what were those views and where were they made?

Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
☐ No

☐ Yes, as described below:

| Column 1 | Name the entity funding the research. |
| Column 2 | Describe the research project. |
| Column 3 | Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
| Column 4 | Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:
Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I will not have any career advancement from my institution by participating in these guidelines

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable

☐ No
☐ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Internal medicine, Thrombosis and Haemostasis (subspecialty)

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☒ No
☐ Yes

If yes, please explain:

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No

☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Prevention of VTE in Surgical Hospitalized Patients</th>
<th>Guideline Panel on Prevention of VTE in Medical Hospitalized Patients</th>
<th>Guideline Panel on Optimal Management of Anticoagulation Therapy</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>5/1/2015; 5/3/2015</td>
<td>Dr. Dentali has COI relevant to all three guideline panels.</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
<td>Yes</td>
<td>2/15/2017 Alexander</td>
<td>Update to disclosures. See Part D.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>Principal investigator for research funded by Bayer (an observational study on the prevalence and risk factors for concomitant deep vein thrombosis in patients with objectively diagnosed superficial vein thrombosis)</td>
<td>04/14/2015</td>
<td>Bayer markets rivaroxaban.</td>
</tr>
<tr>
<td>Boehringer Ingleheim</td>
<td>Personal income from consulting</td>
<td>4/27/2015</td>
<td>BI markets dabigatran.</td>
</tr>
</tbody>
</table>

Notes:
Part D. New Declarations

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehringer Ingelheim</td>
<td>Direct payment for consulting. Dr. Dentali’s previously disclosed consultancy with Boehringer Ingelheim ended in 2016.</td>
<td>02/15/2017</td>
<td>COI. Boehringer Ingelheim markets dabigatran</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No

☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanofi</td>
<td>Ad Board</td>
<td>April 30, 2015</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>Bayer</td>
<td>Ad Board</td>
<td>January 31, 2015</td>
<td>Ended before appointment</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Ad Board</td>
<td>March 31, 2015</td>
<td>Ended before appointment</td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.
Column 2  Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer</td>
<td>EINSTEIN Choice Study</td>
<td>Site PI</td>
<td>Dec‘15</td>
<td>Not a COI: Bayer markets rivaroxaban. However, Dr. Kahn does not have a leadership role in this study, and all funds go to her institution.</td>
</tr>
<tr>
<td></td>
<td>-Funds go to Institution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portola</td>
<td>APEX Study</td>
<td>Site PI</td>
<td>Dec‘15</td>
<td>Not a COI: Portola is developing an anticoagulation reversal agent. However, Dr. Kahn does not have a leadership role in this study, and all funds go to her institution.</td>
</tr>
<tr>
<td></td>
<td>-Funds go to Institution</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests
5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in Surgical Hospitalized Patients and VTE in Medical Hospitalized Patients

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs
1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes
   If yes, please explain:

Previously Published Opinions
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☐ No
   - ☒ Yes
   If yes, what were those views and where were they made?
     - Lead Author, ACCP 9th Ed, Chapter on Preventing VTE in non-surgical patients

Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
   - ☒ No
☐ Yes, as described below:

**Column 1** Name the entity funding the research.

**Column 2** Describe the research project.

**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know

☒ No

☐ Yes

If yes, please explain:
Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   Full support

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No
   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☐ No
   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don’t know or not applicable
   ☐ No
   ☐ Yes

   If yes, please explain:

Professional Specialty
8. What is your primary clinical specialty or subspecialty?

   Internal Medicine and Thrombosis

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☒ Yes

   If yes, please explain:

   Consultation on issues of thromboprophylaxis in clinic and in hospitalized patients
Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☐ No
☒ Yes

If yes, please describe:

I am waiting to hear at end-July if a large Canadian VTE research network grant I submitted will be funded - if funded, it will be a joint public-private partnership, and I will be the PI.

5/5/2015 ASH Internal Note: Potential COI: This research may be considered a conflict of interest, if it is funded by companies with products potentially affected by these guidelines. Even if funding goes to Dr. Kahn’s institution, she will have a leadership role.
### Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>VTE in Surgical Hospitalized Patients and VTE in Medical Hospitalized Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Approved to participate?</strong></td>
<td><strong>Status</strong></td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
<tr>
<td>Yes</td>
<td>Conflicted minority</td>
</tr>
</tbody>
</table>

New interests disclosed. See Part D. These activities occurred after all recommendations were finalized for both the medical (11/17-18/2016) panel and the surgical panel (2/7/2018). Note: On 6/23/2017, FDA approved Portola’s betrixaban, and on 5/3/2018 FDA approved Portola’s andexanet alfa. On appointment, Dr. Kahn disclosed research funding from Portola. As described in Part B above, she did not have a leadership role, and all funding went to her institution.

If status is conflicted minority, summarize all current material interests in affected companies:
<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMS-Pfizer</td>
<td>Direct payments for serving on an advisory board</td>
<td>2/10/17</td>
<td>Pfizer markets apixaban.</td>
</tr>
<tr>
<td>Sanofi Aventis</td>
<td>Direct payments for serving on an advisory board in April 2018</td>
<td>4/21/18</td>
<td>Sanofi markets LMWH.</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Direct payments for serving on an advisory board in Jan 2018</td>
<td>4/21/18</td>
<td>Pfizer marks apixaban.</td>
</tr>
</tbody>
</table>

Notes:
Part D. New Declarations
The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple sources of funding</td>
<td>Co-Principal Investigator for the pan-Canadian VTE research network.</td>
<td>10/13/2016</td>
<td>Not a COI. This network is funded by the Canadian Institutes of Health Research (CIHR) and by industry, including companies that could be affected by ASH VTE guidelines. However, all industry funding is unrestricted and pooled with CIHR funding.</td>
</tr>
<tr>
<td>BMS-Pfizer</td>
<td>Direct payments for serving on an advisory board</td>
<td>2/10/17</td>
<td>COI. Pfizer markets apixaban.</td>
</tr>
<tr>
<td>Sanofi Aventis</td>
<td>Direct payments for serving on an advisory board in April 2018</td>
<td>4/21/18</td>
<td>COI. Sanofi markets LMWH.</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Direct payments for serving on an advisory board in Jan 2018</td>
<td>4/21/18</td>
<td>COI. Pfizer markets apixaban.</td>
</tr>
</tbody>
</table>
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that
develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose,
treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and
other ownership interests but excludes diversified mutual fund shares.

X No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from
any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health
conditions?

X No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To report activities that generate revenues for your institution, see Part B, Question 4.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5.  Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☐ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

**Prevention of VTE in Nonsurgical Patients**

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

**Personal Beliefs**
1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☐ No
   - x Yes
   
   If yes, please explain: As a VTE patient, I am grateful to ASH for leading this important work to help to prevent VTE in non-surgical patients. I strongly believe that the guidelines can prevent others from experiencing the unfortunate and sometime tragic outcomes of VTE.

**Previously Published Opinions**
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - x No
   - ☐ Yes
   
   If yes, what were those views and where were they made?

**Research**
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

   - □ Don’t know
   - X No
   - □ Yes

   If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   - □ Don’t know
   - X No
   - □ Yes

   If yes, please explain:
Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

As a professional at The State University of New York, I anticipate positive support from my institution on the development of guidelines for the prevention of VTE in non-surgical patients. Several SUNY institutions, including Upstate Medical Center, Downstate Medical Center, and Stony Brook University, for example, are strongly invested in the preparation of medical professionals and quality patient care. Should the guidelines generate an unanticipated negative reaction from peers, the academic standards in place for dispute of research findings would apply here, including validation by further research.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☐ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty? Not applicable
9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   X No
   □ Yes

   If yes, please explain:

**Expected Interests**

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

   X No
   □ Yes

   If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Prevention of VTE in Nonsurgical Patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>8/13/15; 8/16/15</td>
<td></td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
</table>

Notes:
Part A. Material Interests in Companies

**Equity**

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patents and Royalties**

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No
☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention of VTE in Medical Hospitalized Patients

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?
   ☒ No
   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   ☐ No
   ☒ Yes

   If yes, what were those views and where were they made?

   I have few publications on this topic (review and original article) as well as few presentations on congresses (please check pubmed to author Rezende SM)

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
☒ No
☐ Yes, as described below:

**Column 1** Name the entity funding the research.

**Column 2** Describe the research project.

**Column 3** Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

**Column 4** Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:
Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I guess this would not harm my position in my institution.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☒ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☒ No
☐ Yes
If yes, please explain:

I recommend diagnostic tests to diagnose venous thrombosis and I treat venous thrombosis.

Expected Interests
10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒  No

☐  Yes

If yes, please describe:
## Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Prevention of VTE in Medical Hospitalized Patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Date reviewed by ASH staff</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/1/2015; 5/3/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>4/25/2018 Alexander</td>
<td>On 4/21/18, Dr. Rezende confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
</table>

Notes:
Part A. Material Interests in Companies

**Equity**

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

- ☒ No

☐ Yes, as described below:

*Add rows as needed for each equity interest.*

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patents and Royalties**

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

- ☒ No

☐ Yes, as described below:

*Add rows as needed for each patent or royalty interest.*

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

<table>
<thead>
<tr>
<th>Topic</th>
<th>Guideline Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous thromboembolism (VTE)</td>
<td>VTE Guideline Coordination Panel</td>
</tr>
<tr>
<td>Prevention of VTE in medical hospitalized patients</td>
<td>Guideline Panel on Prevention of VTE in Medical Hospitalized Patients</td>
</tr>
<tr>
<td>Prevention and treatment of VTE in patients with cancer</td>
<td>Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer</td>
</tr>
<tr>
<td>Diagnosis of VTE</td>
<td>Guideline Panel on Diagnosis of VTE</td>
</tr>
</tbody>
</table>

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs
1. Do you have strongly held beliefs related to the topic of these guidelines?
   - ☒ No
   - ☐ Yes

   If yes, please explain:

Previously Published Opinions
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   - ☐ No
   - ☒ Yes

   If yes, what were those views and where were they made?
   - ACCP AT Guidelines
   - CHEST since edition 6 to 9
   - Cochrane reviews on antithrombotic use in patients with cancer
   - NEJM editorial on update of a systematic review on antithrombotics with cancer
- JAMA Clinical Synopsis – heparin in cancer patients undergoing surgery

**Research**

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name the entity funding the research.</td>
<td>Describe the research project.</td>
<td>Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.</td>
<td>Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)</td>
</tr>
</tbody>
</table>

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR</td>
<td>Individual patient data meta-analysis antithrombotics in cancer</td>
<td>PI</td>
<td>Mach 2016</td>
</tr>
</tbody>
</table>

---

**Institutional Relationships**

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know

☐ No

☒ Yes

If yes, please explain:

Contract for systematic reviews for these guidelines being negotiated with ASH
5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☑️ Don’t know

☐ No

☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

N/A

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☑️ No

☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No

☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable

☐ No

☐ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?
Internal Medicine, Public Health, preventive medicine

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No
☒ Yes

If yes, please explain:

Diagnosis and treatment of DVT

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No
☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

### Name of guideline panel(s)

- VTE Guideline Coordination Panel
- Guideline Panel on Diagnosis of VTE
- Guideline Panel on Prevention of VTE in Medical Hospitalized Patients
- Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Date reviewed by ASH staff</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/1/2015; 5/5/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>4/26/2018 Alexander</td>
<td>On 4/26/2018, Dr. Schunemann confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

Add rows as needed for each patent or royalty interest.
### Company Description Date Divested

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>UptoDate</td>
<td>For chapter on aspirin as primary prophylaxis for cardiovascular disease and cancer</td>
<td></td>
<td>Although Wolters Kluwer’s publishing product UpToDate might be affected by the existence of competitor guidelines such as ASH guidelines, it is unlikely to be affected by what ASH guidelines recommend. Further, UTD practice guidelines would be updated at some point to reflect most current literature (including ASH guideline recommendations).</td>
</tr>
</tbody>
</table>

### Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1  Name the company.

Column 2  Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3  Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.
Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No
☒ Yes, as described below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehringer-Ingelheim</td>
<td>RCT of dabigatran vs warfarin for DVT</td>
<td>Local PI – received no funds</td>
<td>2014</td>
<td>Boehringer Ingelheim markets dabigatran. However, this interest ended before appointment. Furthermore, Dr. Spencer did not have a leadership role and did not receive any funds.</td>
</tr>
</tbody>
</table>
### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

- ☒ No
- ☐ Yes, as described below:

*Add rows as needed for each interest.*

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in Medical Hospitalized Patients

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs
1. Do you have strongly held beliefs related to the topic of these guidelines?
   ☒ No
   ☐ Yes
   If yes, please explain:

Previously Published Opinions
2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   ☒ No
   ☐ Yes
   If yes, what were those views and where were they made?

Research
3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
   ☒ No
☐ Yes, as described below:

| Column 1 Name the entity funding the research. |
| Column 2 Describe the research project. |
| Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe. |
| Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”) |

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don’t know
☒ No
☐ Yes

If yes, please explain:
Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My Chair of Medicine/institution would support my work regardless of reaction from peers.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No
☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No
☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don’t know or not applicable
☐ No
☐ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Thrombosis and Cardiology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No
☒ Yes
If yes, please explain: As a cardiologist I must prescribe DVT prophylaxis (or not prescribe) for my hospital patients.

**Expected Interests**

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No
☐ Yes

If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Prevention of VTE in Medical Hospitalized Patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Review Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/1/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/3/2018 Alexander</td>
<td>On 5/3/2018, Dr. Spencer confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:

[Blank]
Part A. Material Interests in Companies

Equity
1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No
☐ Yes, as described below:

Add rows as needed for each equity interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patents and Royalties
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No
☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Date Divested</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**My Partner’s or Spouse’s Interests**

5. Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>End Date</th>
<th>For ASH Internal Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention of VTE in Medical Hospitalized Patients

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?
   ☒ No
   ☐ Yes
   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
   ☐ No
   ☒ Yes
   If yes, what were those views and where were they made?

   My views are that I am unsure based on available evidence on the risks and benefits of VTE prophylaxis in hospitalized patients. I have presented these views at grand round presentations, and have published on VTE prevention in medical patients.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
☐ No
☒ Yes, as described below:

Column 1  Name the entity funding the research.
Column 2  Describe the research project.
Column 3  Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
Column 4  Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<table>
<thead>
<tr>
<th>Funder</th>
<th>Description of Research</th>
<th>My Role</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTRS</td>
<td>Development of a Risk Assessment model for Hospital-Acquired VTE</td>
<td>PI</td>
<td>2013</td>
</tr>
<tr>
<td>NIH</td>
<td>Validation of a risk assessment model for hospital-acquired VTE in non-surgical patients</td>
<td>PI</td>
<td>Pending submission</td>
</tr>
</tbody>
</table>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?
   ☐ Don’t know
   ☒ No
   ☐ Yes
   If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?
   ☐ Don’t know
☒ No
☐ Yes
If yes, please explain:

Career Advancement
6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I am a tenured associate professor at UVM, my chair and my institution strongly support my research and do not censure me for my research findings in peer reviewed settings or guideline development.

Theoretically, if a peer reviewer were to take exception to the guideline they could scuttle a manuscript or a grant, but I would hope they would not review the manuscript or grant if they could not separate their opinion on a guideline from science.

Advocacy and Policy Positions
7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☐ No
☒ Yes   5/18/15 ASH internal note: ISTH and Hemophilia/Thrombophilia research society

If yes, are you involved in formulating or voting for positions?

☒ No
☐ Yes
If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☒ Don’t know or not applicable
☐ No
☐ Yes
If yes, please explain:
Professional Specialty

8. What is your primary clinical specialty or subspecialty?

   I am board certified in internal medicine, hematology, and medical oncology. I specialize in the treatment of patients with diverse disorders of thrombosis and hemostasis.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☒ Yes

   If yes, please explain: I am a clinician, I recommend measures to prevent venous thrombosis to medical inpatients based on clinical experience and my understanding of the medical literature. I treat individuals with venous thrombosis, and I manage bleeding complications of anticoagulants.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☒ No

    ☐ Yes

    If yes, please describe:
Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

<table>
<thead>
<tr>
<th>Name of guideline panel(s)</th>
<th>Guideline Panel on Prevention of VTE in Medical Hospitalized Patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Approved to participate?</th>
<th>Status</th>
<th>Recusal may be required?</th>
<th>Reviewer Name and Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/1/2015; 5/3/2015</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Unconflicted majority</td>
<td>No</td>
<td>5/3/2018 Alexander</td>
<td>New disclosures. See Part D. Dr. Zakai confirmed all information in this form.</td>
</tr>
</tbody>
</table>

If status is conflicted minority, summarize all current material interests in affected companies:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
## Part D. New Declarations

The following interests were disclosed after appointment:

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Disclosure Date</th>
<th>ASH Internal Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Dr. Zakai did not recertify in medical oncology. His certificate lapsed in 12/2017.</td>
<td>05/03/2018</td>
<td>This is an update to Part B, Question 8.</td>
</tr>
</tbody>
</table>